inotuzumab ozogamicin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia
Trial Timeline
Feb 24, 2023 → Nov 6, 2025
NCT ID
NCT05687032About inotuzumab ozogamicin
inotuzumab ozogamicin is a approved stage product being developed by Pfizer for Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05687032. Target conditions include Acute Lymphoblastic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphoblastic Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03127605 | Pre-clinical | Completed |
| NCT05597085 | Pre-clinical | Completed |
| NCT05687032 | Approved | Completed |
| NCT04307134 | Pre-clinical | Completed |
| NCT04456959 | Pre-clinical | Completed |
| NCT01363297 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia